Astellas Pharma (4503) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Astellas Pharma’s 2026 fiscal year Q1 results showed higher revenue and profits, along with a significant improvement in margins, driven by rapid growth in key strategic products and the lapping of temporary cost factors. Revenue was ¥640.91B (+26.7% year on year), Operating Income was ¥184.51B (+94.9%), and quarterly Net Income attributable to owners of the parent was ¥141.83B (+107.3%). The Operating Income margin improved by 10.1pt to 28.8%, from 18.7% in the same period of the previous year; however, it should be noted that this improvement also includes the temporary effect of lapping the ¥13.55B impairment loss recorded in the same period of the previous year. Top-line growth was led by combined growth of +43% in key strategic products such as PADCEV, IZERVAY, and VYLOY, as disclosed by the Company, as well as +19% growth in the core product XTANDI.

Factors Driving Performance Changes

【Revenue】Revenue increased 26.7% year on year to ¥640.91B. According to Company disclosures, the combined sales of key strategic products—PADCEV, IZERVAY, VYLOY, VEOZAH, and XOSPATA—increased sharply by +43% year on year and was the primary driver of revenue growth. XTANDI, the product with the largest revenue mix, also grew +19% and contributed to the increase in revenue. The Company disclosed a positive foreign-exchange impact of ¥60B on revenue, and yen depreciation—the current-period USD/JPY rate was 159 yen versus 145 yen in the same period of the previous year—was also a contributing factor.

【Profit and Loss】Operating Income increased 94.9% year on year to ¥184.51B, while the Operating Income margin improved by 10.1pt to 28.8%, from 18.7% in the same period of the previous year. The SG&A expense ratio declined to 33.6%, from 38.9% in the previous year, a decrease of 5.4pt, with improved cost efficiency contributing to the increase in profit. In addition, other expenses declined substantially to ¥4.30B, from ¥21.33B in the previous year. This was a temporary factor resulting from the lapping of the ¥13.55B impairment loss recorded in the same period of the previous year, compared with ¥0.05B in the current period. Net finance income turned positive at ¥2.01B, compared with net finance expense of ¥4.23B in the previous year, resulting in Profit Before Tax of ¥186.51B (+106.3%). The effective tax rate was broadly unchanged at 24.0%, compared with 24.3% in the previous year, and Net Income attributable to owners of the parent increased +107.3%, broadly in line with Profit Before Tax. Both revenue and profits increased.

Segment Analysis

The Company operates as a single Pharmaceutical Business segment and therefore omits the presentation of segment information. Accordingly, product-level revenue composition is used as an alternative basis for analysis. XTANDI generated revenue of ¥276.6B, accounting for 43.2% of total revenue, and is the largest core product on a standalone basis. It grew steadily by +19% year on year, and the Company explained that progress was in line with expectations relative to its full-year forecast.

Meanwhile, growth was driven by the key strategic product portfolio: PADCEV (¥75.5B, +36%), IZERVAY (¥27.2B, +70%), VYLOY (¥21.1B, +51%), XOSPATA (¥21.6B, +27%), and VEOZAH (¥14.9B, +55%). The five products generated combined revenue of ¥160.3B, representing 25.0% of total revenue. These key strategic products together with XTANDI accounted for 68.2% of total revenue across six products and are estimated to have driven more than half of the ¥135.12B increase in revenue. Although operating income by product has not been disclosed, it is clear that the strong growth rates of growth products were a major driver of the Company-wide +94.9% increase in Operating Income.

Key Financial Metrics

Profitability: ROE was 7.3% on a quarterly annualized basis, while the Operating Income margin was 28.8%, compared with 18.7% in the same period of the previous year, an improvement of +10.1pt. The gross margin remained high at 80.9%, broadly unchanged from 80.9% in the previous year, or -0.4pt on a strict basis.
Cash flow quality: Operating Cash Flow (OCF)/Net Income was 0.61x, below 1.0x, indicating a delay in the conversion of profit into cash. Free Cash Flow was ¥17.23B (OCF + investing cash flow).
Investment efficiency: Investment in property, plant and equipment was ¥12.62B, compared with total depreciation and amortization of tangible and intangible assets of ¥49.89B, representing 0.25x and indicating a focus on maintaining and renewing existing assets. Including ¥45.53B of intangible asset acquisitions, total investment was ¥58.15B, demonstrating active investment in pipeline assets.
Financial soundness: The Equity Ratio was 52.6%, compared with 51.3% in the previous year, an improvement of +1.3pt. The current ratio was 120.3% (current assets of ¥1,485.60B / current liabilities of ¥1,234.76B).

Cash Flow Analysis

OCF was ¥86.48B (+57.7% year on year and 0.61x Net Income), indicating that cash generation did not increase to the same extent as Profit Before Tax.

Investing cash flow was -¥69.24B, primarily due to ¥12.62B of property, plant and equipment acquisitions, ¥45.53B of intangible asset acquisitions—including pipeline asset acquisitions such as ASP546C, VIR-5500, and ASP7317—and ¥12.25B of acquisitions of equity instruments.

Financing cash flow was -¥52.95B. Dividend payments of ¥69.87B were the largest use of cash, partially offset by a ¥29.87B increase in short-term borrowings. Share repurchases were small at ¥0.59B.

FCF was ¥17.23B (OCF + investing cash flow).

Cash generation assessment: Requires monitoring. A sharp increase in trade receivables (+¥84.89B, +11.4%) and higher corporate income tax payments (-¥62.39B, +86.7% year on year) weighed on OCF growth.

Earnings Quality

As the Company adopts IFRS, the concept of Ordinary Income is not used, and performance is evaluated on a Profit Before Tax basis. The difference between Profit Before Tax of ¥186.51B and Net Income of ¥141.75B consists of income taxes of ¥44.76B, corresponding to an effective tax rate of 24.0%; no unusual divergence unrelated to the tax burden was observed.

However, the improvement in Operating Income includes temporary factors. The lapping of the ¥13.55B impairment loss recorded in the same period of the previous year, compared with ¥0.05B in the current period, contributed to profit growth through the substantial decline in other expenses from ¥21.33B to ¥4.30B. Accordingly, structural improvements in earnings power and temporary factors are intermixed.

Comprehensive Income attributable to owners of the parent of ¥183.70B exceeded Net Income attributable to owners of the parent of ¥141.83B by ¥41.9B. This was primarily due to foreign currency translation adjustments for foreign operations of +¥41.61B, reflecting the effect of yen depreciation, rather than an improvement in underlying business earnings.

Earnings Forecast and Guidance

The Q1 progress rates against the full-year forecasts—Revenue of ¥2,220B, Operating Income of ¥395B, and Net Income of ¥300B—were 28.9% for Revenue, 46.7% for Operating Income, and 47.3% for Net Income attributable to owners of the parent. Compared with standard progress of 25% for Q1, Revenue was +3.9pt ahead, while profit was progressing more than +20pt ahead of schedule. Progress was therefore substantially front-loaded. The Company expects to increase investment in R&D from Q2 onward, and the plan to concentrate R&D expenses in the second half of the fiscal year is considered one reason why profit progress significantly exceeded revenue progress as of Q1. There were no revisions to the earnings forecast or dividend forecast for the current quarter.

Shareholder Returns

The full-year dividend forecast is ¥80 per share, implying a Payout Ratio of approximately 47.8% against full-year forecast EPS of ¥167.46. The current-quarter statement of cash flows records dividend payments of ¥69.87B, but these relate to the payment of the dividend for the previous fiscal year-end and were not covered by current-quarter FCF of ¥17.23B. Share repurchases were small at ¥0.59B, indicating a shareholder return policy centered on dividends.

Catalysts

【Short Term】An earnings briefing for securities analysts and institutional investors is scheduled for August 5, 2026. Increased penetration of PADCEV for the U.S. MIBC indication and progress in VYLOY’s Phase III LUCERNA trial—the target number of patient enrollments has already been achieved ahead of schedule—are expected to be reflected in future performance.

【Long Term】Key areas of focus include the start of enrollment in Phase III trials for setidegrasib and ASP2138, expansion of the Claudin18.2-targeted portfolio comprising VYLOY, ASP2138, and ASP546C, and progress under Sustainable Margin Transformation, which targets ¥200B in cost reductions during fiscal years 2026–2030.

Industry Benchmark (Reference, Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Returns

Profitability was substantially above the industry median and positioned at a high level.

Growth and Capital Efficiency

Revenue growth also substantially exceeded the industry median, indicating a high growth rate within the industry.

Source: Compiled by the Company

Risk Factors

1. Increase in refund liabilities (U.S. rebates): Refund liabilities increased to ¥448.32B, from ¥422.56B at the end of the previous fiscal year, an increase of +6.1%. This suggests increasing pricing negotiation and chargeback pressure in the U.S. market and could potentially weigh on the gross margin.

2. Delay in cash conversion: OCF/Net Income was 0.61x, primarily due to an increase of ¥84.89B (+11.4%) in trade receivables. Cash generation has not kept pace with profit growth, making improvement from the next quarter onward a key monitoring point.

3. Increasing reliance on intangible assets and goodwill: Intangible assets reached ¥1,227.0B, or 27.7% of total assets, while goodwill reached ¥450.48B, or 23.2% of net assets. The Company also acquired ¥45.53B of intangible assets, including pipeline assets, during the quarter, requiring close monitoring of future impairment risk.

Key Takeaways from the Earnings Results

1. The Operating Income margin improved from 18.7% to 28.8%, an increase of 10.1pt, but this improvement includes the temporary effect of lapping the ¥13.55B impairment loss recorded in the same period of the previous year. Both structural cost efficiencies, reflected in the 5.4pt decline in the SG&A expense ratio, and temporary factors contributed; this should be considered when assessing earnings quality.

2. Full-year progress was 46–47% on a profit basis, substantially above the standard progress rate of 25%. As the Company has indicated a policy of increasing R&D investment in the second half, the earnings profile is structured such that profits are more likely to be front-loaded in the first half.

3. While OCF remained at 0.61x Net Income, trade receivables increased by double digits. Compared with the improvement in revenue and profit, cash generation has lagged somewhat, making future trends in cash conversion an area to monitor.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit 5-year fade period). It is not a forecast of the market share price or a recommendation to take any specific investment action.

Sensitivity: ¥1,311–¥1,388 for a ±1% change in the cost of equity, and ¥1,342–¥1,358 for a ±0.1 change in ω.

Notes:

• The EPS impact of approximately ¥4.9 per share resulting from a ±¥5 change in the assumed exchange rate is reflected in the bear/bull scenarios.
• Because Net Income progress against the full-year forecast was 47%, above the standard 25%, forecast EPS has been adjusted upward within a maximum range of +10% (as companies progressing ahead of schedule tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net assets as of the quarter-end are used, resulting in a timing difference relative to the full-year forecast.

(Calculation model: Residual Income Model / Interest rate reference month: 2026-07 / This value does not forecast or guarantee a future share price)

---

This report is an earnings analysis document automatically generated through AI-integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a very strong start, with revenue growth, substantial operating-margin expansion and profit growth materially ahead of the full-year run-rate implied by company guidance. Revenue increased 26.7% year on year to ¥640.9bn. Operating income rose 94.9% to ¥184.5bn. Net income more than doubled, increasing 107.3% to ¥141.8bn. The operating margin expanded to 28.8% from 18.7% a year earlier, a sharp 1,008bp improvement. Gross margin was 80.9%, down modestly by 0.4 percentage points year on year, indicating that the operating-margin expansion was not principally a gross-margin story. Gross profit nevertheless increased ¥107.2bn, more than covering the combined ¥31.1bn increase in SG&A, R&D and intangible-asset amortization. SG&A excluding R&D and intangible amortization grew 9.2%, materially below revenue growth, demonstrating favorable operating leverage. R&D expense increased 14.0% to ¥81.7bn, preserving investment in the pipeline while remaining below the revenue growth rate. The decline in other expenses to ¥4.3bn from ¥21.3bn was also a major contributor to the year-on-year earnings acceleration, with the prior year including ¥13.6bn of impairment losses versus only ¥0.5bn this quarter. Finance income exceeded finance costs by ¥2.0bn, compared with a net finance cost of ¥4.2bn in the prior-year quarter. The effective tax rate was 24.0%, resulting in a normal tax burden factor of 0.760. Annualized ROE was 29.2%, well above the 15% benchmark for excellent profitability. Cash conversion was weaker than accounting earnings, as operating cash flow of ¥86.5bn represented only 0.61x net income. The primary cash-flow drag was a ¥70.9bn increase in trade and other receivables, alongside ¥62.4bn of tax payments. Full-year revenue progress reached 28.9% against the standard 25% Q1 pace, while operating-income and net-income progress of 46.7% and 47.3%, respectively, were substantially ahead of the standard pace. This creates a high earnings base for the remainder of FY2027, although part of the quarterly profit outperformance reflects the absence of the prior-year impairment charge and therefore should not be extrapolated mechanically. Management maintained both earnings and dividend guidance, leaving the FY2027 forecast unchanged.

Profitability Analysis

The annualized DuPont ROE of 29.2% is decomposed into a 22.1% net profit margin, 0.694x annualized asset turnover and 1.90x financial leverage. The principal improvement driver was margin expansion: operating margin increased 1,008bp year on year to 28.8%, while net margin increased to 22.1% from 13.5%, a 860bp expansion. Asset turnover of 0.694x is consistent with a pharmaceutical business that has a substantial IP and acquisition-related asset base. Financial leverage of 1.90x supports ROE but does not appear excessive given the 52.6% equity ratio and reported 0.90x debt-to-equity ratio. Gross margin declined slightly to 80.9% from 81.2%, so pricing, product mix and production economics did not provide the main source of margin improvement. Instead, the expansion reflects operating leverage: revenue rose ¥135.1bn while SG&A excluding R&D and amortization increased only ¥18.1bn. R&D intensity was 12.8% of revenue, below the 15-20% innovator-pharma benchmark but still representing a 14.0% year-on-year increase in absolute investment. Intangible-asset amortization rose 8.9% to ¥35.7bn, remaining a meaningful recurring cost of the company’s IP-led portfolio. Other expenses fell by ¥17.0bn, including a sharp reduction in impairment losses, and this non-recurring comparison benefit amplified the operating-income growth rate. The tax burden of 0.760 and interest burden of 1.011 are favorable, with net finance income contributing modestly to pre-tax earnings. The operating margin is excellent by pharmaceutical and general corporate benchmarks, but the sustainability of the nearly doubled operating profit depends on maintaining sales momentum while avoiding a return of material impairments or expense normalization.

Growth Assessment

Top-line momentum was strong, with 26.7% revenue growth to ¥640.9bn. Revenue exceeded the standard Q1 progress rate against FY2027 guidance by 3.9 percentage points, reaching 28.9% of the ¥2,220.0bn full-year target. Profit growth was much faster than revenue growth, as operating income increased 94.9% and net income increased 107.3%. The ¥107.2bn increase in gross profit was the core funding source for higher commercial and R&D investment. Expense discipline enhanced scalability, as SG&A excluding R&D and intangible amortization grew only 9.2% year on year. R&D expense grew ¥10.0bn to ¥81.7bn, supporting continued pipeline development but resulting in an R&D intensity of 12.8%. The lower other-expense burden and minimal current-quarter impairment losses contributed significantly to profit growth, reducing the recurrence quality of the headline year-on-year operating-profit increase. Full-year operating-income progress was 46.7%, 21.7 percentage points ahead of the normal 25% Q1 pace. Net-income progress was 47.3%, also 22.3 percentage points above the standard pace. The current pace therefore offers considerable headroom versus unchanged guidance, but quarterly pharmaceutical results can be affected by product demand, rebate and refund-liability movements, foreign exchange, regulatory events and R&D-related charges. The single pharmaceutical-business segment means profitability is driven by the consolidated portfolio rather than diversification across separately disclosed operating segments.

Financial Health

The balance sheet is adequately capitalized, with total equity of ¥1,944.4bn and an equity ratio of 52.6%, up from 51.3% a year earlier. Total liabilities were ¥1,748.1bn, equivalent to 47.3% of total assets. The reported debt-to-equity ratio was 0.90x, below the 2.0x level associated with aggressive leverage. Interest-bearing bonds and borrowings totaled ¥589.9bn, comprising ¥269.9bn current and ¥320.0bn non-current. The current ratio was 1.20x, calculated from ¥1,485.6bn of current assets and ¥1,234.8bn of current liabilities; it is above 1.0x but below the 1.5x healthy benchmark. Current assets exceed current liabilities by ¥250.8bn, providing a positive working-capital buffer. Cash and cash equivalents of ¥244.7bn cover 90.7% of current bonds and borrowings, while receivables and other financial assets provide additional liquidity. The company therefore does not show an immediate maturity mismatch, although the relatively large ¥269.9bn of short-term borrowings warrants monitoring against cash generation and refinancing conditions. Goodwill was ¥450.5bn, equal to 23.2% of equity and below the 30% healthy benchmark. Intangible assets were ¥1,022.7bn, or 27.7% of assets, making the asset base materially dependent on marketed-product rights and pipeline-related IP valuations. This IP-heavy balance sheet is typical of an acquisitive innovator pharmaceutical company but leaves capital value sensitive to clinical, commercial and impairment outcomes. Refund liabilities were ¥448.3bn and represented a significant current-liability category, requiring continued monitoring of estimates, rebates and product-return dynamics.

Notable B/S Changes

Trade and other receivables: +¥84.9bn versus FY2026 year-end (+11.4%) to ¥831.7bn - the increase is the principal driver of the Q1 cash-conversion shortfall and should be monitored for collection timing and sales quality. Intangible assets: +¥25.8bn versus FY2026 year-end (+2.6%) to ¥1,022.7bn - IP assets remain 27.7% of total assets, maintaining meaningful exposure to amortization and impairment outcomes. Goodwill: +¥9.3bn versus FY2026 year-end (+2.1%) to ¥450.5bn - the increase is modest, while goodwill remains at a manageable 23.2% of equity. Current bonds and borrowings: +¥23.9bn versus FY2026 year-end (+9.7%) to ¥269.9bn - short-term funding increased and should be viewed alongside the quarter-end cash decline. Equity attributable to owners: +¥113.6bn versus FY2026 year-end (+6.2%) to ¥1,942.7bn - strong Q1 profit and positive foreign-currency translation OCI more than offset dividends paid.

Cash Flow Quality

Operating cash flow was ¥86.5bn, rising from ¥54.8bn in the prior-year quarter but trailing net income of ¥141.8bn. The OCF-to-net-income ratio was 0.61x, below the 0.8x quality threshold and therefore a potential earnings-quality concern. The principal driver was a ¥70.9bn use of cash from higher trade and other receivables, indicating that part of the strong reported sales growth had not yet converted into cash at quarter-end. Inventory consumed a further ¥3.3bn of cash, and inventory days of 251 are materially above the stated 90-day and 60-day alert thresholds. For pharmaceuticals, elevated inventory can reflect manufacturing lead times, launch preparation, supply-resilience policies or demand assumptions, but the level heightens risks of inventory write-downs, expiry and weaker future production efficiency if sales do not absorb stock. Other working-capital changes used ¥17.7bn, while income-tax payments of ¥62.4bn also reduced cash conversion. The accruals ratio of 1.5% remains low and does not signal broad-based accrual distortion; the cash-flow shortfall is concentrated in identifiable working-capital and tax items. Capital expenditure was ¥12.6bn and intangible-asset purchases were ¥45.5bn. Free cash flow was ¥17.2bn under the reported measure, after including the quarter's investment requirements. This free cash flow did not cover ¥69.9bn of dividends paid during the quarter, resulting in a net cash decrease of ¥36.9bn. The cash balance remained substantial at ¥244.7bn, but sustainable improvement in receivable collection and inventory efficiency would strengthen confidence in earnings conversion.

Dividend Sustainability

FY2027 dividend guidance is ¥80.0 per share, unchanged from the company forecast. Based on forecast EPS of ¥167.46, the implied dividend payout ratio is 47.8%, below the 60% sustainability benchmark. The projected payout is therefore supported by forecast accounting earnings. Q1 dividends paid of ¥69.9bn were equivalent to 49.3% of Q1 net income, broadly consistent with the forecast payout profile. Share repurchases were limited to ¥0.6bn in Q1. Including the small buyback, the Q1 total return ratio was approximately 49.7% of net income. Reported free cash flow of ¥17.2bn did not cover Q1 dividends, principally because operating cash flow lagged earnings and intangible acquisitions rose to ¥45.5bn. The current-period cash funding gap is manageable in view of ¥244.7bn of cash and the company’s capital base, but sustained dividend coverage will depend on normalization of receivables and stronger operating cash conversion. The unchanged dividend outlook is consistent with management confidence in full-year earnings, though cash-flow execution remains the key variable for assessing the quality of that coverage.

Risk Assessment

Business risks include Pharmaceutical portfolio risk: revenue and earnings are exposed to product-demand volatility, reimbursement and rebate dynamics, generic or biosimilar competition, pricing reforms and patent-expiry effects., Pipeline and regulatory risk: the ¥1,022.7bn intangible-asset base and ongoing ¥81.7bn quarterly R&D spend make valuation and future growth sensitive to clinical outcomes, approval decisions and commercialization execution., Inventory risk: inventory days of 251 are elevated; if demand, launch assumptions or supply plans are not realized, expiry, write-down and manufacturing-efficiency risks could increase., Foreign-exchange risk: ¥41.6bn of foreign-currency translation gains in OCI demonstrate that equity and reported comprehensive income are sensitive to exchange-rate movements..

Financial risks include Cash-conversion risk: operating cash flow covered only 0.61x of net income, below the 0.8x alert threshold, driven mainly by a ¥70.9bn receivables increase., Short-term funding and refinancing risk: ¥269.9bn of bonds and borrowings are current, although current assets exceed current liabilities and liquidity is currently adequate., IP valuation risk: intangible assets equal 27.7% of total assets and goodwill equals 23.2% of equity; adverse clinical or commercial developments could create impairment risk., Refund-liability estimation risk: refund liabilities of ¥448.3bn are substantial and changes in rebate, return or payer assumptions could affect revenue recognition and cash flow..

Key concerns include High priority: convert the strong Q1 profit result into cash by reducing receivable growth and improving inventory turnover., High priority: distinguish recurring sales and operating leverage from the year-on-year benefit of sharply lower other expenses and impairment losses., Medium priority: monitor whether operating-income progress of 46.7% versus the full-year forecast can be retained as quarterly spending, launch costs and R&D activity develop., Medium priority: preserve balance-sheet flexibility while funding intangible-asset investment, dividends and current-debt refinancing..

Investment Implications

Key takeaways include Q1 revenue growth of 26.7% and operating-margin expansion to 28.8% produced exceptional profit growth., Annualized ROE of 29.2% is excellent, supported primarily by a 22.1% net margin rather than excessive financial leverage., Operating-income and net-income progress versus full-year guidance were materially ahead of a normal Q1 seasonal pace., The most important counterweight is weak cash conversion, with OCF/net income at 0.61x and a large receivables build., The balance sheet is solidly equity-funded, but intangible assets and goodwill make long-term value dependent on IP and pipeline performance., The forecast dividend payout ratio of 47.8% appears earnings-supported, while free-cash-flow coverage should be monitored..

Metrics to watch include Revenue growth and operating-margin retention relative to the 28.8% Q1 margin, Receivables growth and operating cash flow relative to net income, Inventory days, inventory provisions and product-demand indicators, R&D intensity and the progression of development programs, Intangible-asset additions, amortization and impairment charges, Refund-liability movements and their effect on recognized revenue, Progress against FY2027 revenue, operating-income and net-income guidance, Dividend cash coverage and net cash movement.

Regarding relative positioning, Astellas combines very high Q1 profitability, strong operating leverage and a conservatively capitalized balance sheet with a more IP-intensive asset structure and weaker near-term cash conversion than the accounting earnings profile suggests. The 80.9% gross margin and 28.8% operating margin are consistent with a high-value branded-pharmaceutical model, while the 12.8% R&D intensity is below the 15-20% innovator-pharma benchmark and should be assessed alongside pipeline output and business-development activity.